MDMA

Thursday

Nick Carter

MDMA should be licensed for veterans with PTSD

‘Stuff starts to get real, real quick,’ recalls former US Marine, Tyler Flanigan. An Iraqi sniper had just shot out the tyres of his truck and a key member of his team had been killed. ‘We were sitting ducks.’ ‘I couldn’t easily name a single day in Iraq that I wasn’t shot at or didn’t have something explode next to me,’ says his fellow US Marine veteran, Nigel McCourry. Combat experience is hard to forget. Civilian life offers daily triggers that throw you back down ‘IED alley’, reliving the flailing feeling of being blown up and the horror of gathering friends’ body parts in bags. These former US Marines discussed

Tuesday

Mia Levitin

Are hallucinogenic drugs losing their stigma?

We are in the midst of a ‘psychedelic renaissance’. Not since the 1950s and early 1960s has there been so much interest in researching the therapeutic potential of psychedelics. The FDA approved a ketamine derivative for medicinal use in 2019, and has given both MDMA and psilocybin (the psycho-active ingredient in magic mushrooms) ‘breakthrough therapy’ status, putting the drugs on a fast track to approval in the US, with the UK likely to follow suit. Professor David Nutt is a neuropsycho-pharmacologist (say that three times fast) and head of the Centre for Psychedelic Research at Imperial College, London. He was the UK’s ‘drug tsar’ before getting sacked in 2009 for